Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma (Q36512499)

14 August 2017

1 reference

title

Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma (English)

1 reference

14 August 2017

1 reference

Peter Anderson

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

2

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

333-343

1 reference

Overview of sarcomas in the adolescent and young adult population

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Current treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Bisphosphonates and radiation therapy for palliation of metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Bisphosphonates: new therapeutic agents for the treatment of bone tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Carrier-based strategies for targeting protein and peptide drugs to the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Liposomal, nanoparticle, and conjugated formulations of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

21 January 2018

Macrophages and cancer

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Therapy of cancer metastasis by systemic activation of macrophages: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Increased Fas expression reduces the metastatic potential of human osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethanolamine in the treatment of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Chronic ifosfamide nephrotoxicity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Evaluating risk factors for the development of ifosfamide encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Methylene blue reversal of ifosfamide-related encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/14796694.2.3.333

21 January 2018

Identifiers

DOI

10.2217/14796694.2.3.333

1 reference

14 August 2017

1 reference